Claritus Pharmaceuticals Inc. (CLAZF)

[StockLogistics]

Late 2022 long time to wait

“A Phase 2 clinical trial of R-107 in PPHN is now planned for late 2022. This study should position Claritas in the forefront of companies addressing this critically important orphan drug market, and, if the Phase 2 study is successful, Claritas will seek to monetize this program through either an out-license or sale.”